N-(2-hydroxy-5-methylphenyl)-N'-(4-ethylphenyl)thiourea | 1015420-54-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(2-hydroxy-5-methylphenyl)-N'-(4-ethylphenyl)thiourea
• 英文别名: 1-(4-Ethylphenyl)-3-(2-hydroxy-5-methylphenyl)thiourea；1-(4-ethylphenyl)-3-(2-hydroxy-5-methylphenyl)thiourea
• CAS: 1015420-54-8
• 化学式: C₁₆H₁₈N₂OS
• 分子量: 286.398
• InChiKey: NCBNJBUZLBJVPW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  76.4
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(2-hydroxy-5-methylphenyl)-N'-(4-ethylphenyl)thiourea 在 potassium superoxide 作用下， 以 乙腈 为溶剂， 反应 12.0h， 生成 N-(4-ethylphenyl)-5-methylbenzo[d]oxazol-2-amine
  参考文献：
  名称：

  Synthesis and evaluation of benzoxazole derivatives as 5-lipoxygenase inhibitors

  摘要：

  5-Lipoxygenase (5-LOX) is important enzyme in the biosynthesis of leukotrienes, and is a potential target in the treatment of asthma and allergy. We designed and synthesized a series of benzoxazoles and benzothiazoles as 5-LOX inhibitors. Fourteen compounds prepared showed the inhibition of LTC4 formation with IC50 value of 0.12-23.88 mu M. Also two compounds 2d and 2g showed improved airway hypersensitiveness. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2010.08.047
• 作为产物：
  描述：

  2-硝基-4-甲苯酚 在 palladium on activated charcoal 氢气 作用下， 以 甲醇 为溶剂， 反应 29.0h， 生成 N-(2-hydroxy-5-methylphenyl)-N'-(4-ethylphenyl)thiourea
  参考文献：
  名称：

  WO2008/35956

  摘要：

  公开号：

文献信息

• [EN] NEW BENZOXAZOLE DERIVATIVE, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME<br/>[FR] NOUVEAU DÉRIVÉ DE BENZOXAZOLE, SON PROCÉDÉ DE PRÉPARATION ET COMPOSITION PHARMACEUTIQUE LE RENFERMANT
  申请人：UNIV EWHA IND COLLABORATION

  公开号：WO2008035956A1

  公开（公告）日：2008-03-27

  [EN] The present invention relates to a new benzoxazole derivative having 5-lipoxygenase inhibitory activity, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The benzoxazole derivative according to the present invention has excellent 5-lipoxygenase inhibitory activity, reduces the degree of airway hypersensitivity, levels of cytokines IL-4, IL-5, and IL- 13, Ova-specific IgE in serum, and degree of the peribronchial and perivascular inflammation, statistically significantly reduces the number of TRAP(+) MNCs, and significantly inhibits osteoclastogenesis in a co-culture system of bone marrow cells and osteoblasts, thereby being used to prevent and treat diseases induced by leukotriene, in particular, inflammatory diseases including asthma or osteoporosis.
  [FR] L'invention concerne un nouveau dérivé de benzoxazole ayant une activité inhibitrice de 5-lipoxygénase, son procédé de préparation et une composition pharmaceutique le renfermant. Le dérivé de benzoxazole selon l'invention possède une excellente activité inhibitrice de 5-lipoxygénase, réduit le degré d'hypersensibilité bronchique, les taux de cytokines IL-4, IL-5 et IL- 13, d'IgE spécifique à l'OVA dans le sérum et le degré de l'inflammation péribronchique et périvasculaire, réduit sensiblement sur le plan statistique le nombre de TRAP(+) MNCs et empêche sensiblement l'ostéoclastogenèse dans un système de co-culture de cellules de moelle osseuse et d'ostéoblastes, que l'on utilise alors pour empêcher et pour traiter des maladies induites par le leucotriène, en particulier des maladies inflammatoires dont l'asthme et l'ostéoporose.
• Synthesis and evaluation of benzoxazole derivatives as 5-lipoxygenase inhibitors
  作者：Hyunmin Song、Sei-Ryang Oh、Hyeong-Kyu Lee、Gyoonhee Han、Joo-Heon Kim、Hyeun Wook Chang、Kyung-Eun Doh、Hee-Kyung Rhee、Hea-Young Park Choo

  DOI：10.1016/j.bmc.2010.08.047

  日期：2010.11

  5-Lipoxygenase (5-LOX) is important enzyme in the biosynthesis of leukotrienes, and is a potential target in the treatment of asthma and allergy. We designed and synthesized a series of benzoxazoles and benzothiazoles as 5-LOX inhibitors. Fourteen compounds prepared showed the inhibition of LTC4 formation with IC50 value of 0.12-23.88 mu M. Also two compounds 2d and 2g showed improved airway hypersensitiveness. (C) 2010 Elsevier Ltd. All rights reserved.
• WO2008/35956
  申请人：——

  公开号：——

  公开（公告）日：——